A Guidetti1, A Mazzocchi2, R Miceli3, E Paterno'4, F Taverna2, F Spina4, F Crippa5, L Farina4, P Corradini1, A M Gianni4, S Viviani6. 1. Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Onco-Hematology, University of Milano, Milan, Italy. 2. Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3. Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 6. Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: simonetta.viviani@istitutotumori.mi.it.
Abstract
BACKGROUND: Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. METHODS: Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. FINDINGS: 101 patients out of 116 had baseline TARC above 800pg/ml (median value 27515pg/ml (IQR, 11001-68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556pg/ml (IQR, 378-977pg/ml). TARC-1 values below 800pg/ml were associated with success of therapy (p=0.0003) and PET-2 negativity (p=0.001). TARC-1≤800pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p<0.0001) and in both subgroups of advanced (p=0.003) and early stage patients (p=0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p=0.0035). INTERPRETATION: Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.
BACKGROUND: Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. METHODS: Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. FINDINGS: 101 patients out of 116 had baseline TARC above 800pg/ml (median value 27515pg/ml (IQR, 11001-68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556pg/ml (IQR, 378-977pg/ml). TARC-1 values below 800pg/ml were associated with success of therapy (p=0.0003) and PET-2 negativity (p=0.001). TARC-1≤800pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p<0.0001) and in both subgroups of advanced (p=0.003) and early stage patients (p=0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p=0.0035). INTERPRETATION: Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.
Authors: Esther E E Drees; Yvonne W S Jauw; Erik van Dijk; Sven Borchmann; Sandra A W M Verkuijlen; Phylicia Stathi; Nils J Groenewegen; Nathalie J Hijmering; Daniella R A I Berry; Eric J Meershoek; Danielle Hoogmoed; Anne Kwakman; Tessa J Molenaar; Dirk M Pegtel; Bauke Ylstra; Daphne de Jong; Josée M Zijlstra; Margaretha G M Roemer Journal: Hemasphere Date: 2022-07-04
Authors: Eline A M Zijtregtop; Friederike Meyer-Wentrup; Wai-Chu Wong; Raoull Hoogendijk; Marta Lopez-Yurda; Christian M Zwaan; Auke Beishuizen Journal: EJHaem Date: 2020-07-04
Authors: Carlos A Ramos; Natalie S Grover; Anne W Beaven; Premal D Lulla; Meng-Fen Wu; Anastasia Ivanova; Tao Wang; Thomas C Shea; Cliona M Rooney; Christopher Dittus; Steven I Park; Adrian P Gee; Paul W Eldridge; Kathryn L McKay; Birju Mehta; Catherine J Cheng; Faith B Buchanan; Bambi J Grilley; Kaitlin Morrison; Malcolm K Brenner; Jonathan S Serody; Gianpietro Dotti; Helen E Heslop; Barbara Savoldo Journal: J Clin Oncol Date: 2020-07-23 Impact factor: 50.717
Authors: Wouter J Plattel; Lydia Visser; Arjan Diepstra; Andor W J M Glaudemans; Marcel Nijland; Tom van Meerten; Hanneke C Kluin-Nelemans; Gustaaf W van Imhoff; Anke van den Berg Journal: Br J Haematol Date: 2020-02-27 Impact factor: 6.998
Authors: Alessandra Romano; Chiara Pavoni; Francesco Di Raimondo; Corrado Tarella; Simonetta Viviani; Andrea Rossi; Caterina Patti; Marco Picardi; Maria Cantonetti; Giorgio La Nasa; Livio Trentin; Silvia Bolis; Valerio Zoli; Paolo Gavarotti; Paolo Corradini; Michele Cimminiello; Corrado Schiavotto; Guido Parvis; Roberta Zanotti; Guido Gini; Andrés J M Ferreri; Piera Viero; Stephane Chauvie; Alberto Biggi; Alessandro Massimo Gianni; Andrea Gallamini; Alessandro Rambaldi Journal: Cancer Med Date: 2020-11-06 Impact factor: 4.452
Authors: Esther E E Drees; Margaretha G M Roemer; Nils J Groenewegen; Jennifer Perez-Boza; Monique A J van Eijndhoven; Leah I Prins; Sandra A W M Verkuijlen; Xuan-Mai Tran; Julia Driessen; G J C Zwezerijnen; Phylicia Stathi; Kevin Mol; Joey J J P Karregat; Aikaterini Kalantidou; Andrea Vallés-Martí; T J Molenaar; Ernesto Aparicio-Puerta; Erik van Dijk; Bauke Ylstra; Catharina G M Groothuis-Oudshoorn; Michael Hackenberg; Daphne de Jong; Josée M Zijlstra; D Michiel Pegtel Journal: J Extracell Vesicles Date: 2021-07-15